Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B
Condition: Hepatitis B, Chronic Intervention: Other: Stopping Sponsors: Göteborg University; Sahlgrenska University Hospital, Sweden Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 14, 2022 Category: Research Source Type: clinical trials
A New Class of Antiviral Therapy Could Treat COVID-19
SAN FRANCISCO, Dec. 9, 2021. As the SARS-CoV-2 virus mutates, new variants emerge that can better evade immunity and spread more widely. This causes an ongoing race, in which scientists and pharmaceutical companies must continually test and adapt... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 9, 2021 Category: Pharmaceuticals Source Type: clinical trials
YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial
This study aims to test the integrative medicine (Chinese medicine plus antiviral therapy) effective on lowing hepatocellular carcinoma risk among patients with hepatitis-related compensated liver cirrhosis.Methods and analysisThis is a multi-center randomized controlled trial, and a total of 5 hospitals and 802 patients will be involved in. All the subjects are randomly allocated to the YinQiSanHuang Jiedu decoction (YQSHD) group (n = 401) or the placebo group (n = 401). The YQSHD group receives YQSHD granule with entecavir (ETV), and the placebo group receives YQSHD placebo with ETV. The treatment period will last for 52...
Source: Trials - October 14, 2021 Category: Research Source Type: clinical trials
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial
This study is a 4-arm (parallel group), multicenter, randomized (2:2:1:1 ratio), partly double-blind, controlled trial to evaluate the safety and efficacy of convalescent plasma (CP) or camostat mesylate with control or placebo in adult patients diagnosed with SARS-CoV-2 infection and high risk for progression to moderate/severe COVID-19. Superiority of the intervention arms will be tested.ParticipantsThe trial is conducted at 10 –15 tertiary care centers in Germany. Individuals aged 18 years or above with ability to provide written informed consent with SARS-CoV-2 infection, confirmed by PCR within 3 days or less be...
Source: Trials - May 17, 2021 Category: Research Source Type: clinical trials
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
Condition: Portal Hypertension Intervention: Sponsor: Nanfang Hospital of Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2021 Category: Research Source Type: clinical trials
